MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.56
+0.56 (+8.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.00
Open7.05
Bid5.90 x 800
Ask7.90 x 1200
Day's Range7.05 - 7.76
52 Week Range3.31 - 9.87
Volume1,204,492
Avg. Volume610,120
Market Cap306.369M
Beta3.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire20 days ago

    Marinus Pharmaceuticals to Present at the Baird Healthcare Conference

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M. Cashman, Chief Executive Officer will present a company overview at the Baird 2018 Healthcare Conference on Thursday, September 6, 2018 at 2:00 p.m. ET.  The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • GlobeNewswire22 days ago

    Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...

  • GlobeNewswirelast month

    Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward F. Smith, Chief Financial Officer will present a company overview at the Wedbush/PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 4:15 p.m. ET.  The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results

    RADNOR, Pa., Aug. 02, 2018-- Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided ...

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 50,000 shares of its common stock to a new employee, with a grant date of July 27, 2018. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

  • ACCESSWIRE2 months ago

    Free Technical Research on Marinus Pharma and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within Marinus Pharmaceuticals, Valley National, BB&T, Cognizant Technology Solutions, Cinemark, and International Game Technology — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, June 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Marinus ...

  • GlobeNewswire3 months ago

    Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index

    “We are pleased with Marinus’ addition to the Russell indexes,” said Christopher M. Cashman, Chief Executive Officer of Marinus. Russell US Indexes are the leading US equity benchmarks for institutional investors.

  • ACCESSWIRE3 months ago

    Free Technical Reports on MannKind and Three Additional Biotech Equities

    This morning, WallStEquities.com is focused on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation today are these four equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).

  • ACCESSWIRE4 months ago

    Mayo Clinic-Backed NMTC Could Be Worth 3X This Year

    For 1/3 of epilepsy patients, drugs won't control their seizures. Surgery may be an option (curative for some patients) but figuring out on what part of the brain to operate may require major brain surgery first: costly and invasive. This kind of event could put a lot of eyeballs on NMTC, and the stock has room to run as it goes through its first price discovery period.

  • ACCESSWIRE9 months ago

    Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...

  • ACCESSWIRE10 months ago

    Today’s Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.

    NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Marinus Pharmaceuticals closed up 14% higher on Thursday after SAGE Therapeutics revealed positive clinical trial data for a postpartum depression ...